The HER2 receptor is a tyrosine kinase that drives breast cancer commonly designated as HER2+ve subtype. In these patients, the HER2 receptor protein is either overexpressed and/or harbor mutations occurring In various segments of this receptor. We are specifically stucying how the mutations occurring in the direrization domain might alter the dynamics of signaling, thereby promoting toahe reSIStaNCE HER2 targeted therapies. Understanding the downstream signaling switches that occur in presence of specific acquired mutations would help develop effective precision treatment. As HER2 oncogenic types like M also well In some other cancer overexpression known gastric cancer, relevance of these findings are expected to impact clinical practices in those areas as well.